InterMune Inc. (NASDAQ: ITMN) gained Friday after Reuters reported the company is attracting takeover interest. In the view of Wells Fargo analyst Brian Abrahams, the possibility is realistic. InterMune Inc. (NASDAQ:ITMN) stock opened at $30.83 in last session, and closed at $33.87, while the day range of InterMune Inc. (NASDAQ:ITMN) stock is $29.97 – $35.58. The stock showed a positive weekly performance of 12.75%.
CEL-SCI Corporation (NYSEMKT:CVM) on Feb. 27 reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date. CEL-SCI Corporation (NYSEMKT:CVM) stock opened at $1.30 in last session, and closed at $1.41 by gaining 11.90%. The 52 week range of $0.53 – $3.09. Company’s market capitalization is $67.98 million.
Zacks upgraded shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) from an underperform rating to a neutral rating in a research note released on Thursday morning, American Banking News reports. They currently have $62.50 target price on the stock. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock increased 10.60% and finished the last session at $55.53. The EPS of the stock remained -2.20. Company’s market capitalization is $1.63 billion.
Zogenix, Inc. (NASDAQ: ZGNX) just took a painful one-two punch on the market yesterday, causing shares to fall 15%. First, the company reported Q4 earnings, which missed estimates; but that wasn’t the real story with the company yesterday. Zogenix, Inc. (NASDAQ:ZGNX) stock opened the session at $3.98, and closed the session at $4.04. The 52 week range of the Zogenix, Inc. (NASDAQ:ZGNX) stock remained $1.25 – $5.19 and the day range was $3.85 – $4.09.